NASDAQ:MNOV - MediciNova Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.00
  • Forecasted Upside: 254.22 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.67
▲ +0.04 (1.10%)

This chart shows the closing price for MNOV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MediciNova Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MNOV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MNOV

Analyst Price Target is $13.00
▲ +254.22% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for MediciNova in the last 3 months. The average price target is $13.00, with a high forecast of $15.00 and a low forecast of $11.00. The average price target represents a 254.22% upside from the last price of $3.67.

This chart shows the closing price for MNOV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in MediciNova. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/9/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/9/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/7/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/10/2021Maxim GroupInitiated CoverageBuy$15.00High
8/3/2020B. RileyReiterated RatingBuy$11.00Low
4/8/2020B. RileyReiterated RatingBuy$11.00High
3/13/2020B. RileyLower Price TargetBuy$22.00 ➝ $11.00High
3/25/2019B. RileyReiterated RatingBuy ➝ Buy$22.00High
3/28/2018B. RileyInitiated CoverageBuy$22.00High
4/18/2017Credit Suisse GroupInitiated CoverageOutperform ➝ OutperformHigh
(Data available from 8/2/2016 forward)
MediciNova logo
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.
Read More

Today's Range

Now: $3.67
Low: $3.55
High: $3.71

50 Day Range

MA: $3.98
Low: $3.54
High: $4.32

52 Week Range

Now: $3.67
Low: $3.48
High: $10.81

Volume

76,657 shs

Average Volume

810,437 shs

Market Capitalization

$178.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.43

Frequently Asked Questions

What sell-side analysts currently cover shares of MediciNova?

The following equities research analysts have issued reports on MediciNova in the last twelve months: B. Riley, and Maxim Group.
View the latest analyst ratings for MNOV.

What is the current price target for MediciNova?

2 Wall Street analysts have set twelve-month price targets for MediciNova in the last year. Their average twelve-month price target is $13.00, suggesting a possible upside of 254.2%. Maxim Group has the highest price target set, predicting MNOV will reach $15.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $11.00 for MediciNova in the next year.
View the latest price targets for MNOV.

What is the current consensus analyst rating for MediciNova?

MediciNova currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MNOV will outperform the market and that investors should add to their positions of MediciNova.
View the latest ratings for MNOV.

What other companies compete with MediciNova?

How do I contact MediciNova's investor relations team?

MediciNova's physical mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company's listed phone number is 858-373-1500 and its investor relations email address is [email protected] The official website for MediciNova is medicinova.com.